Jacobsen Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$287K Sell
10,081
-370
-4% -$9.8K 0.08% 96
2026
Q2
$252K Sell
10,451
-529
-5% -$13.8K 0.07% 102
2026
Q1
$308K Buy
10,980
+337
+3% +$8.97K 0.1% 83
2025
Q4
$265K Buy
10,643
+503
+5% +$12.7K 0.09% 92
2025
Q3
$258K Buy
+10,140
New +$250K 0.09% 94
2025
Q2
– Sell
-9,715
Closed -$246K – 122
2025
Q1
$246K Buy
9,715
+1,033
+12% +$27K 0.11% 83
2024
Q4
$230K Sell
8,682
-1,733
-17% -$47K 0.1% 82
2024
Q3
$301K Buy
10,415
+120
+1% +$3.5K 0.13% 63
2024
Q2
$288K Buy
+10,295
New +$283K 0.13% 65
2024
Q1
– Sell
-7,661
Closed -$221K – 94
2023
Q4
$221K Buy
+7,661
New +$232K 0.11% 77

Other funds holding PFE

Jacobsen Capital Management's PFE Position: Q3 2026 in Review

Jacobsen Capital Management reduced its Pfizer (PFE) stake by 3.5% in Q3 2026, selling an estimated $9.8K and leaving 10,081 shares worth $287K. The position accounts for 0.08% of the portfolio, ranked #96.

Jacobsen Capital Management first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. The position peaked at $308K in Q1 2026. 2,346 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Jacobsen Capital Management held 10,081 shares of Pfizer worth $287K as of Q3 2026.
  • Jacobsen Capital Management sold 370 Pfizer shares in Q3 2026, an estimated $9.8K.
  • Pfizer made up 0.08% of Jacobsen Capital Management's portfolio in Q3 2026, its #96 holding.
  • Jacobsen Capital Management first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • Jacobsen Capital Management's Pfizer position peaked at $308K in Q1 2026.
  • 2,346 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Jacobsen Capital Management's 13F filing for Q3 2026, filed 27 Oct 2026.